A comparison study of rivaroxaban mono-therapy and standard-therapy with enoxaparin adjusted by CYP2C9 and VKORC1 genotypes in symptomatic pulmonary embolism patients with or without deep venous thrombosis (DVT).
Phase of Trial: Phase IV
Latest Information Update: 22 Feb 2017
At a glance
- Drugs Enoxaparin sodium (Primary) ; Rivaroxaban (Primary) ; Vitamin K antagonists
- Indications Pulmonary embolism
- Focus Therapeutic Use
- 22 Feb 2017 New trial record